CEO Michele Garufi told BioWorld Today that Nicox SA's eye-drop form of cetirizine "has a good chance to take a nice market share" in eye itching related to allergic conjunctivitis (AC), and could win priority review, thanks to data in pediatric patients. "Of course, [market success] will depend on the partner that we select for commercialization," he added. Talks are under way.